IMR Press / EJGO / Volume 39 / Issue 6 / DOI: 10.12892/ejgo4121.2018

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research
Concentration of serotonin in perimenopausal women with ductal breast cancer and polycystic ovary syndrome
Show Less
1 Laboratory of Menopause and Andropause, Pomeranian Medical University, Szczecin, Poland
2 Department of Biogenic Amines, Polish Academy of Sciences, Lodz, Poland
3 Department of Endocrinology, Metabolic and Internal Diseases, Pomeranian Medical University, Szczecin, Poland
Eur. J. Gynaecol. Oncol. 2018, 39(6), 884–888;
Published: 10 December 2018

Purpose of Investigation: To analyze a relationship between histological grade of ductal breast cancer (BC) and intratumor concentration of serotonin in women with polycystic ovarian syndrome (PCOS), and to study the long-term effects of innovative neurohormonal therapy in this group. Materials and Methods: The study included 65 women (28 premenopausal and 37 postmenopausal, age 43-69 years) with PCOS and BC. Aside from mastectomy, chemotherapy and menopausal status-specific hormonal treatment, all subjects received metformin, quinagolide, melatonin, and methysergide maleate. Serum concentrations of sex hormones were determined post-mastectomy and after five and ten years. Results: Intratumoral concentrations of serotonin in grade II and III BC were higher than in grade I tumors. After ten years, all subjects had normal concentrations of estrogens, prolactin, and serotonin, and showed no signs of BC recurrence. Conclusion: Intratumor level of serotonin may serve as a marker of BC aggressiveness. Neurohormonal therapy may prevent progression of BC.
Sex hormones
Breast cancer
Polycystic ovary syndrome
Back to top